ClinicalTrials.gg
RecruitingNCT02756091I-IDISUpdated Nov 13, 2024

International Intracranial Dissection Study

An observational study in Cerebrovascular Disorders, Vascular: Intracranial and Intimal Dissection, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.

Primary conditionStrokeRegistry: Cerebrovascular DisordersReclassifiedWhy we changed it
Registry
Cerebrovascular Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stroke
Why
  1. The study's listed conditions name Stroke, a narrower term within Cerebrovascular Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern — 7 open to participants now, 7 under way, 1 of them phase 3. Stroke · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
4th of 11
500 · median 447
Started
2016
with 2 others
Observational
11 of 19
4 open now
Registered
9th of 19
by date

Among the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2016, is one of 11 observational ones, and was the 9th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

Cervicocerebral artery dissection is a major cause for stroke in young adults. While knowledge of cervical artery dissection (CeAD) has increased thanks to a number of high quality studies, knowledge on intracranial artery dissection (IAD) is limited. Due to treatment and publication bias little is known about the natural history of IAD. Overall, IAD is assumed to have a more severe course than CeAD, with a more ominous outcome in patients with subarachnoid hemorrhage (SAH). Furthermore, little information is available on the risk of recurrent IAD as well as on the risk of recurrent ischemic and haemorrhagic events in non-Asian patients. Radiological diagnosis of IAD can be challenging given the small size of intracranial arteries, and the subtle and non-specific radiological signs which tend to evolve over time. The optimal treatment of IAD is unknown. There are no randomised trials and only observational studies with relatively small sample sizes are available, thus providing a very low level of evidence.

Finding the factors that are decisive for outcome and recurrence after intracranial artery dissection is key to an improved management of this potentially severe disease predominantly affecting young patients. By using standardised protocols for diagnosis, imaging and follow-up, the investigators intend to obtain large representative patient samples in order to fill the gap of evidence.

Read the detailed description

Cervicocephalic artery dissection corresponds to a hematoma in the wall of a cervical or an intracranial artery and is an important cause of stroke in children and young and middle-aged adults. While extracranial cervical artery dissection (CeAD) has been extensively studied and described, less information is available on pure intracranial artery dissection (IAD) not involving the cervical portion of the artery. Early reports were based exclusively on autopsy series, hence biased towards the most severe cases. The incidence of IAD is unknown, but is probably lower than the incidence of symptomatic CeAD in populations of European origin. The proportion of IAD among all cervicocephalic dissections varies substantially between ethnic and age groups, and depending on study recruitment strategies and ascertainment methods. Indeed, recruitments through departments of neurology are biased towards CeAD and IAD presenting with local symptoms and/or ischaemic stroke while recruitments through departments of neurosurgery or interventional neuroradiology are biased towards IAD presenting with subarachnoid haemorrhage (SAH).Therefore, patients with IAD are managed not only by neurologists, but also by neurosurgeons, and interventional neuroradiologists, each having an incomplete picture of the disease.

The vast majority of reported series of IAD patients come from Asian countries and IAD affects the posterior circulation more frequently than the anterior circulation in these series. This contrasts with CeAD and saccular intracranial aneurysms, which most commonly affect the anterior circulation. Due to treatment and publication bias little is known about the natural history of IAD. Overall, IAD is assumed to have a more severe course than CeAD, with a more ominous outcome in patients with SAH IAD than in patients with non-SAH IAD. Furthermore, little information is available on the risk of recurrent IAD as well as risk for recurrent ischaemic and haemorrhagic events. Radiological diagnosis of IAD can be challenging given the small size of intracranial arteries, and the subtle and non-specific radiological signs which tend to evolve with time.

The optimal treatment of IAD is unknown. There are no randomised trials and only observational studies with relatively small sample sizes are available, thus providing a very low level of evidence. Patients with SAH IAD are usually treated by surgery or endovascular procedures because up to 40% of the patients experience re-bleeding within the first days after the event. Various surgical and endovascular treatment methods have been proposed for intracranial dissecting aneurysms. When patients are in poor clinical condition or treatment has an unacceptably high complication risk, it can be decided to withhold from surgical or endovascular treatment. In addition, Most non-SAH IAD patients have been treated medically, but the choice of antithrombotic therapy (anticoagulants or antiplatelet agents) has been evaluated neither in randomised trials nor in systematic reviews and meta-analyses of observational data. As a consequence, there is currently no consensus on optimal treatment of IAD.

03

Conditions studied

  • Cerebrovascular Disorders
  • Vascular: Intracranial
  • Intimal Dissection
  • Stroke

Browse trials for

Keywords

  • Intracranial Artery Dissection
  • IAD
  • Stroke
  • Observational Study
04

In context

Stroke Reclassified

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

This study's planned enrollment of 500 is above the median of 150 across 1,971 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.

Compared within Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cerebrovascular Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients are recruited in a consecutive ongoing recruitment process in daily clinical practice.

Patients who are hospitalized in participant sites are screened by authorized study group members according to local daily practice. If the patient matches the selection criteria (inclusion and exclusion criteria)he/she is enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute Intracranial Artery Dissection (symptom onset ≤ 30 days)
  • Age ≥ 18 years
  • Consent to participate according to local requirements

Exclusion criteria

Exclusion Criteria:

  • Iatrogenic dissection caused by endovascular intervention
  • Extracranial dissection with intracranial extension
06

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherNo study-specific intervention
07

What researchers measure

Primary outcomes

  1. Modified Rankin Scale score (mRS score)

    The mRS is a standardised valid measure to semi-quantify functional outcome after stroke.

    Time frame: 180 days after diagnosis +/- 30 days

  2. Recurrence of stroke

    Time frame: 180 days after diagnosis

Secondary outcomes

  1. Recurrence of cervico- cerebral dissection

    Time frame: 90 days, 180 days, 12 months

  2. Recurrence of stroke

    Time frame: 0-10 days, 90 days, 12 months after diagnosis

  3. Change in Modified Rankin Scale score (mRS score) from before diagnosis to follow up

    The mRS is a standardised valid measure to semi-quantify functional outcome after stroke.

    Time frame: 0-10 days, 90 days, 12 months after diagnosis

  4. Change in occupational status from before diagnosis to follow up

    The patients' profession, workload (whether the patient is full time or part time working) and, if the patient is not working, the reason why he or she is not working (e.g. for medical reason) are assessed by patient interview according to local routine procedure.

    Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis

  5. Mortality

    Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis

  6. Increase or reduction in size (>50% local degree of stenosis) or disappearance of stenosis at 6 months (in patients with stenotic and occlusive dissection)

    Assessed by radiological assessments according to local routine procedures.

    Time frame: 180 days after diagnosis

  7. Increase or reduction in size (> 20% maximal diameter) of aneurysms at 6 months (in patients with aneurysm)

    Assessed by radiological assessments according to local routine procedures.

    Time frame: 180 days after diagnosis

Other outcomes

  1. Personal and familiar risk factors for intracranial artery dissection

    Assessment of personal and familiar risk factors according to local routine procedures (may differ according to local standard). Risk factors will be elicited by patient questionnaire or by questioning of patients' next of kin.

    Time frame: 0-10 days after diagnosis

  2. Laboratory parameters assessed by blood test

    Assessment of laboratory findings according to local routine procedures (may differ according to local standard).

    Time frame: 90 days, 180 days, 12 months

  3. Radiological findings assessed by magnetic resonance imaging (MRI), magnetic resonance angiography, computed tomography (CT), computed tomography angiography, digital subtraction angiography or duplex sonography

    Assessment of radiological findings according to local routine procedures (may differ according to local standard).

    Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis

  4. Localization of intracranial artery dissection

    Localization of intracranial artery dissection by imaging modalities according to local routine procedures (may differ according to local standard).

    Time frame: 0-10 days after diagnosis

  5. Demographic variables

    Assessment of demographic variables according to local routine procedures (may differ according to local standard). Demographic variables will be elicited by patient questionnaire or by questioning of patients' next of kin.

    Time frame: 0-10 days after diagnosis

08

Study locations

3 of 3 sites recruiting
  • National Cerebral and Cardiovascular Center Osaka
    Osaka, Kansai 565-8565, Japan
    Recruiting
    • Masatoshi Koga, MD, PHD · Principal investigator
  • Department of Neurology, University Hospital Basel
    Basel, Basel- Stadt 4056, Switzerland
    Recruiting
    • Engelter Stefan, Prof. Dr. med. · Principal investigator
  • Department of Neurology, Inselspital Bern
    Bern, 3010, Switzerland
    Recruiting
    • Marcel Arnold, Prof. Dr. med. · Principal investigator
    • Barbara Goeggel-Simonetti, Dr. med. · Principal investigator
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Nov 2026 and a completion of Nov 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
Apr 29, 2016
Start
Aug 2016
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2027
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02756091
Collaborators
Swiss Heart Foundation, Cervical Artery Dissections and Ischemic Stroke Patients - Consortium
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Aug 2016
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 13, 2024

Study contacts

Marcel Arnold, Prof. Dr. med.
Contact
marcel.arnold@insel.ch
Barbara Goeggel Simonetti, Dr. med.
Contact
Barbara.GoeggelSimonetti@insel.ch
Marcel Arnold, Prof. Dr. med.
principal investigator · Neurology Department, Inselspital University Hospital Bern
Barbara Goeggel Simonetti, Dr. med.
principal investigator · Neurology Department, Inselspital University Hospital Bern
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion